Nivolumab-Induced Uveitis in Kidney Cancer Patient
Author Information
Author(s): Hitomi Imai, Tomoyuki Koguchi, Yuki Harigane, Kei Yaginuma, Satoru Meguro, Seiji Hoshi, Junya Hata, Hidenori Akaihata, Soichiro Ogawa, Yoshiyuki Kojima
Primary Institution: Fukushima Medical University School of Medicine
Hypothesis
Can nivolumab treatment induce Vogt-Koyanagi-Harada disease-like uveitis in patients with metastatic renal cell carcinoma?
Conclusion
Nivolumab effectively controlled cancer progression despite inducing Vogt-Koyanagi-Harada disease-like uveitis.
Supporting Evidence
- The patient developed VKH-like uveitis as an immune-related adverse event of nivolumab.
- Topical steroids improved the uveitis while nivolumab treatment continued.
- HLA-DR4 expression was significantly higher in lung metastases than in primary renal cancer.
Takeaway
A man with kidney cancer got a rare eye problem from his treatment, but the treatment still worked to help his cancer.
Methodology
Case report detailing the patient's treatment and response to nivolumab and subsequent development of uveitis.
Limitations
Only one case is reported, limiting generalizability.
Participant Demographics
68-year-old male with metastatic renal cell carcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website